Ultraviolet A/blue light-emitting diode therapy for vulvovaginal candidiasis: a case presentation

  • Mariana Robatto
  • Maria Clara Pavie
  • Igor Garcia
  • Manoela Porto Menezes
  • Milena Bastos
  • Handerson Jorge Dourado Leite
  • Andreia Noites
  • Patrícia LordeloEmail author
Original Article


Vulvovaginal candidiasis (VVC) is a frequent infection of the female genitourinary tract. It is considered the second most common genital infection in women, after bacterial vaginosis. VVC is treated with oral or topical azole derivatives. However, these agents may lead to adverse reactions and their chronic use might lead to resistance to antifungal agents. Given that the ultraviolet A/blue light-emitting diode (LED) is an electromagnetic radiation source with antimicrobial properties, it is hypothesized that this resource may be a non-drug alternative to the treatment of vulvovaginitis. A technical/experimental safety test was conducted to characterize the light source spectrum and temperature generation of the device, followed by a pilot study in a 52-year-old patient with a clinical diagnosis of VVC confirmed by culture and examination of fresh vaginal samples, owing to the presence of lumpy vaginal discharge and a complaint of pruritus. The vulva and vagina were exposed to 401 ± 5 nm ultraviolet A/blue LED irradiation in a single session, divided into two applications. A reassessment was performed 21 days after the treatment. The light-emitting device had a visible spectrum, in the violet and blue ranges, and a maximum temperature increase of 7 °C. During the reassessment, the culture was found to be negative for fungus, and the signs and symptoms of the patient had disappeared. A light-emitting device with a spectrum in the range of 401 ± 5 nm could potentially be an alternative treatment modality for women with VVC, as it led to the resolution of clinical and microbiological problems in our patient.


Vulvovaginal candidiasis Women Phototherapy 



This work would not have been possible without the intellectual discussions about the research of the PhD Physiotherapist Caroline Constante and Engineer Décio Minalle (DGM Eletronica).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed were in accordance with the ethical standards of the institutional and/or national research committee and with the declaration of Helsinki of 1964 and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from the patient included in the study.


  1. 1.
    Chew SY, Than LT (2016) Vulvovaginal candidosis: contemporary challenges and the future of prophylactic and therapeutic approaches. Mycoses. 59(5):262–273. CrossRefGoogle Scholar
  2. 2.
    Liu MB, Xu SR, He Y, Deng GH, Sheng HF, Huang XM et al (2013) Diverse vaginal microbiomes in reproductive-age women with vulvovaginal candidiasis. PLoS One 8(11):e79812. CrossRefGoogle Scholar
  3. 3.
    Fidel PL Jr, Barousse M, Espinosa T, Ficarra M, Sturtevant J, Martin DH et al (2004) An intravaginal live Candida challenge in humans leads to new hypotheses for the immunopathogenesis of vulvovaginal candidiasis. Infect Immun 72(5):2939–2946. CrossRefGoogle Scholar
  4. 4.
    Apalata T, Longo-Mbenza B, Sturm A, Carr W, Moodley P (2014) Factors associated with symptomatic vulvovaginal candidiasis: a study among women attending a primary healthcare clinic in Kwazulu-Natal, South Africa. Ann Med Health Sci Res 4(3):410–416. CrossRefGoogle Scholar
  5. 5.
    Rathod SD, Klausner JD, Krupp K, Reingold AL, Madhivanan P (2012) Epidemiologic features of vulvovaginal candidiasis among reproductive-age women in India. Infect Dis Obstet Gynecol 2012:859071. CrossRefGoogle Scholar
  6. 6.
    Mårdh PA, Rodrigues AG, Genç M, Novikova N, Martinez-de-Oliveira J, Guaschino S (2002) Facts and myths on recurrent vulvovaginal candidosis--a review on epidemiology, clinical manifestations, diagnosis, pathogenesis and therapy. Int J STD AIDS 13(8):522–539. CrossRefGoogle Scholar
  7. 7.
    Dovnik A, Golle A, Novak D, Arko D, Takač I (2015) Treatment of vulvovaginal candidiasis: a review of the literature. Acta Dermatovenerol Alp Pannonica Adriat 24(1):5–7. Google Scholar
  8. 8.
    Xie HY, Feng D, Wei DM, Mei L, Chen H, Wang X et al (2017) Probiotics for vulvovaginal candidiasis in non-pregnant women. Cochrane Database Syst Rev.
  9. 9.
    Murdock LE, Mckenzie K, Maclean M, Macgregor SJ, Anderson JG (2013) Lethal effects of high-intensity violet 405-nm light on Saccharomyces cerevisiae, Candida albicans and on dormant and germinating spores of Aspergillus niger. Fungal Biol 117(7–8):519–527. CrossRefGoogle Scholar
  10. 10.
    Imada K, Tanaka S, Ibaraki Y, Yoshimura K, Ito S (2014) Antifungal effect of 405-nm light on Botrytis cinerea. Lett Appl Microbiol 59(6):670–676. CrossRefGoogle Scholar
  11. 11.
    Guffey JS, Wilborn J (2006) In vitro bactericidal effects of 405-nm and 470-nm blue light. Photomed Laser Surg 24(6):684–688. CrossRefGoogle Scholar
  12. 12.
    Ablon G (2018) Phototherapy with light emitting diodes: treating a broad range of medical and aesthetic conditions in dermatology. J Clin Aesthet Dermatol 11(2):21–27Google Scholar
  13. 13.
    Barolet D (2008) Light-emitting diodes (LEDs) in dermatology. Semin Cutan Med Surg 27(4):227–238. CrossRefGoogle Scholar
  14. 14.
    Adamskaya N, Dungel P, Mittermayr R, Hartinger J, Feichtinger G, Wassermann K et al (2011) Light therapy by blue LED improves wound healing in an excision model in rats. Injury. 42(9):917–921.
  15. 15.
    Watson C, Calabretto H (2007) Comprehensive review of conventional and non-conventional methods of management of recurrent vulvovaginal candidiasis. Aust N Z J Obstet Gynaecol 47(4):262–272. CrossRefGoogle Scholar
  16. 16.
    Jenkins PA, Carroll JD (2011) How to report low-level laser therapy (LLLT)/photomedicine dose and beam parameters in clinical and laboratory studies. Photomed Laser Surg 29(12):785–787. CrossRefGoogle Scholar
  17. 17.
    Henderson BW, Waldow SM, Potter WR, Dougherty TJ (1985) Interaction of photodynamic therapy and hyperthermia: tumor response and cell survival studies after treatment of mice in vivo. Cancer Res 45(12 Pt 1):6071–6077Google Scholar
  18. 18.
    Maclean M, Mckenzie K, Anderson JG, Gettinby G, Macgregor SJ (2014) 405 nm light technology for the inactivation of pathogens and its potential role for environmental disinfection and infections control. J Hosp Infect 88(1):1–11. CrossRefGoogle Scholar
  19. 19.
    Inamura T, Tatehara S, Takebe Y, Tokuyama R, Ohshima T, Maeda N et al (2014) Antibacterial and antifungal effect of 405 nm monochromatic laser on endodontopathogenic. Int J Photoenergy:1–7.
  20. 20.
    Robatto M, Pavie MC, Tozetto S, Brito MB, Lordêlo P (2017) Blue light emitting diode in treatment of recurring vulvovaginal candidiasis: a case report. Braz J Med Hum Health 5(4):162–168. Google Scholar
  21. 21.
    Ganz RA, Viveiros J, Ahmad A, Ahmadi A, Khalil A, Tolkoff J et al (2005) Helicobacter pylori in patients can be killed by visible light. Lasers Surg Med 36(4):260–265. CrossRefGoogle Scholar
  22. 22.
    Gold MH, Sensing W, Biron JA (2011) Clinical efficacy of home-use blue-light therapy for mild-to moderate acne. J Cosmet Laser Ther 13(6):308–314. CrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Ltd., part of Springer Nature 2019

Authors and Affiliations

  • Mariana Robatto
    • 1
    • 2
  • Maria Clara Pavie
    • 1
    • 2
  • Igor Garcia
    • 1
  • Manoela Porto Menezes
    • 1
    • 2
  • Milena Bastos
    • 1
  • Handerson Jorge Dourado Leite
    • 1
  • Andreia Noites
    • 3
  • Patrícia Lordelo
    • 1
    • 2
    Email author
  1. 1.Bahiana School of Medicine and Public HealthSalvadorBrazil
  2. 2.Center for Care of Pelvic FloorSalvadorBrazil
  3. 3.School of Allied Health TechnologiesPolytechnic Institute of PortoPortoPortugal

Personalised recommendations